Professor Mark Atkinson, Chairman
 University of Florida, Gainesville, Florida, USA. Department of Pathology, Immunology and Laboratory Medicine.

Professor of Diabetes Research, Professor Atkinson was part of one of the first group of researchers to identify the value of measuring immune responses against GAD in persons with type 1 diabetes. Professor Atkinson's research extends to understanding the immunological mechanisms underlying the formation of diabetes, with his primary research goal involving the development of an effective method for preventing and reversing type 1 diabetes. Professor Atkinson has been a member of the Scientific and Medical Advisory Board since 1997, and is a Board member in Diamyd Medical since 2018.

Professor Daniel Kaufman
 UCLA School of Medicine, Los Angeles, California, USA. Department of Molecular and Medical Pharmacology.

Professor in Molecular and Medical Pharmacology. Professor Kaufman's research is focused on studies in the field of autoimmunity, particularly type 1 diabetes (T1D) and understanding the disease mechanisms in order to develop novel therapeutics in mouse models that could potentially be translated to clinical use. Using preclinical models, Dr. Kaufman’s lab helped to develop some of the GAD and GABA-based diagnostics and therapeutics for T1D that are in clinical use or are being tested in clinical trials. Professor Kaufman and his lab have shown that immune cells have receptors for GABA and that activation of these receptors can inhibit T1D, MS, rheumatoid arthritis, as well as inflammation in type 2 diabetes. In addition, Professor Kaufman and others, have shown that activating GABA receptors on the insulin-producing beta cells can promote the survival and replication of the beta cells. Professor Kaufman has been a member of the Scientific and Medical Advisory Board since 1996.

Professor Åke Lernmark
 Lund University/CRC, Malmö, Sweden, Department of Clinical Sciences.

Professor in Experimental Diabetes Research, Professor Lernmark has focused his research on diabetes and at an early stage identified the antigen that later proved to be GAD. He and his colleagues were the first to clone GAD65 from human islets using biochemical methods,and was thus the first to define autoantibodies against GAD65 in patients with type 1 diabetes. Professor Lernmark was first to use molecular methods to identify HLA genes that are necessary to develop the disorder. Professor Lernmark has been a member of the Scientific and Medical Advisory Board since 1996.

Professor David Leslie
 Royal London and St. Bartholomew's School of Medicine, University of London, UK.

Professor of Diabetes and Autoimmunity. Professor Leslie has been Director of the British Diabetic Twin Study since 1982, the world's largest twin study of its type and Principal Investigator of the European Action LADA consortium. By studying twins, Professor Leslie has been able to show the possibilities for predicting and preventing autoimmune diabetes. Professor Leslie has been a member of the Scientific and Medical Advisory Board since 1999.

Order GAD for preclinical research